- Home
- EDIT vs NMAI Comparison
EDIT vs NMAI Comparison
Compare EDIT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | NMAI |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.8M | 468.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | NMAI |
|---|---|---|
| Price | $2.91 | $13.81 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $6.10 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 123.5K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.28 |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $11.99 |
| 52 Week High | $4.33 | $15.06 |
Technical Indicators
Market Signals| Indicator | EDIT | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 44.21 |
| Support Level | $2.46 | $13.49 |
| Resistance Level | $3.18 | $13.90 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 70.14 | 38.66 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.